Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded at StockNews.com

by · The Cerbat Gem

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday.

Other research analysts have also issued reports about the company. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday. Truist Financial lifted their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Finally, Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.00.

Read Our Latest Analysis on AMRX

Amneal Pharmaceuticals Trading Up 5.4 %

AMRX stock traded up $0.47 during midday trading on Monday, hitting $9.20. 2,220,320 shares of the company’s stock were exchanged, compared to its average volume of 1,409,931. The business has a 50-day simple moving average of $8.53 and a two-hundred day simple moving average of $7.56. The stock has a market capitalization of $2.85 billion, a PE ratio of -13.53 and a beta of 1.17. Amneal Pharmaceuticals has a 1-year low of $4.15 and a 1-year high of $9.32.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. The business had revenue of $701.78 million during the quarter, compared to analysts’ expectations of $657.43 million. As a group, research analysts expect that Amneal Pharmaceuticals will post 0.52 EPS for the current fiscal year.

Institutional Trading of Amneal Pharmaceuticals

A number of large investors have recently made changes to their positions in AMRX. Rothschild Investment LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $37,000. DekaBank Deutsche Girozentrale purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $42,000. nVerses Capital LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at approximately $62,000. Finally, Atlanta Consulting Group Advisors LLC purchased a new stake in Amneal Pharmaceuticals during the 1st quarter valued at approximately $61,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

(Get Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

See Also